"Selecting the optimal treatment for postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer (MBC) remains a challenge, given a preponderance of data for several approved therapeutics. This challenge has been a topic of interest in interviews with oncology leaders, as well as in a comprehensive Peer Exchange discussion.
One facet of the discussion, entitled “Metastatic Breast Cancer Treatment Challenges,” featured managing the side effects associated with mTOR inhibitors. The advent of novel therapies has heightened the need for clinicians to be well-informed on potential adverse events (AEs) associated with these agents to help ensure that patients adhere to their regimens and complete treatment.
The FDA first approved the mTOR inhibitor everolimus (Afinitor) in 2009 for patients with advanced renal cell carcinoma after treatment failure with sorafenib or sunitinib. Everolimus also is approved for the treatment of advanced pancreatic neuroendocrine tumors that are unresectable, locally advanced, or metastatic.
Last year the FDA approved everolimus for the treatment of HR-positive, HER2-negative breast cancer, when given in combination with the aromatase inhibitor (AI) exemestane, in previously treated postmenopausal women, based on findings of the BOLERO-2 trial.